Passionate about Progress
We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) to treat serious chronic cough conditions by targeting the central and peripheral nervous systems.
We are currently investigating Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) where we previously announced positive results from our Phase 2 CANAL trial. We are preparing to initiate the next clinical trial of Haduvio for the treatment of chronic cough in patients with IPF and are focusing future clinical development on chronic cough conditions, including interstitial lung diseases, and refractory chronic cough.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT and we are proud to be part of its vibrant life-science community.
“At Trevi Therapeutics, we are dedicated to the exploration and development of Haduvio for patients suffering from serious neurologically mediated chronic cough conditions where there are no approved treatment options. I am proud of the team that we have developed and their passion for improving patients’ lives.”
– Jennifer Good, Co-Founder, President & CEO